Intech Investment Management LLC Sells 57,659 Shares of HCA Healthcare, Inc. $HCA

Intech Investment Management LLC trimmed its stake in HCA Healthcare, Inc. (NYSE:HCA – Free Report) by 51.3% in the 3rd quarter, Holdings Channel.com reports. The institutional investor owned 54,727 shares of the company’s stock after selling 57,659 shares during the period. Intech Investment Management LLC’s holdings in HCA Healthcare were worth $23,354,000 at the end of the most recent quarter.

A number of other institutional investors have also modified their holdings of the stock. SBI Securities Co. Ltd. raised its stake in shares of HCA Healthcare by 24.7% during the third quarter. SBI Securities Co. Ltd. now owns 111 shares of the company’s stock valued at $47,000 after acquiring an additional 22 shares in the last quarter. Beacon Capital Management LLC increased its holdings in HCA Healthcare by 0.7% during the 3rd quarter. Beacon Capital Management LLC now owns 3,631 shares of the company’s stock worth $1,550,000 after purchasing an additional 25 shares during the period. Diversify Advisory Services LLC raised its position in HCA Healthcare by 3.3% during the 3rd quarter. Diversify Advisory Services LLC now owns 806 shares of the company’s stock valued at $378,000 after purchasing an additional 26 shares in the last quarter. Gryphon Financial Partners LLC raised its position in HCA Healthcare by 1.6% during the 3rd quarter. Gryphon Financial Partners LLC now owns 1,798 shares of the company’s stock valued at $767,000 after purchasing an additional 28 shares in the last quarter. Finally, AdvisorNet Financial Inc lifted its holdings in shares of HCA Healthcare by 3.5% in the 3rd quarter. AdvisorNet Financial Inc now owns 994 shares of the company’s stock worth $468,000 after buying an additional 34 shares during the period. 62.73% of the stock is owned by hedge funds and other institutional investors.

HCA Healthcare Stock Down 0.0%

Shares of HCA opened at $498.82 on Monday. The company has a market cap of $104.20 billion, a price-to-earnings ratio of 16.53, a price-to-earnings-growth ratio of 1.67 and a beta of 1.11. HCA Healthcare, Inc. has a twelve month low of $353.99 and a twelve month high of $556.52. The company has a 50 day moving average of $452.79 and a two-hundred day moving average of $445.91.

HCA Healthcare (NYSE:HCA – Get Free Report) last released its quarterly earnings results on Tuesday, October 27th. The company reported $7.22 earnings per share (EPS) for the quarter, topping the consensus estimate of $6.65 by $0.57. HCA Healthcare had a net margin of 8.61% and a negative return on equity of 198.52%. The business had revenue of $19.85 billion for the quarter, compared to analyst estimates of $19.33 billion. During the same period in the previous year, the company earned $6.96 earnings per share. The business’s revenue for the quarter was up 3.6% on a year-over-year basis. On average, sell-side analysts expect that HCA Healthcare, Inc. will post 30.14 EPS for the current year.

HCA Healthcare Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Tuesday, December 29th. Investors of record on Tuesday, December 15th will be paid a dividend of $0.78 per share. This represents a $3.12 annualized dividend and a yield of 0.6%. The ex-dividend date is Tuesday, December 15th. HCA Healthcare’s payout ratio is 10.34%.

Insider Activity at HCA Healthcare

In related news, EVP Michael Schlosser sold 1,200 shares of the company’s stock in a transaction dated Wednesday, November 4th. The stock was sold at an average price of $494.65, for a total transaction of $593,580.00. Following the transaction, the executive vice president directly owned 1,443 shares of the company’s stock, valued at $713,779.95. This represents a 45.40% decrease in their position. The sale was disclosed in a filing with the SEC, which is available at this link. Also, COO Jon Foster sold 21,713 shares of the firm’s stock in a transaction dated Friday, November 6th. The stock was sold at an average price of $494.95, for a total value of $10,746,849.35. Following the completion of the sale, the chief operating officer directly owned 10,000 shares of the company’s stock, valued at approximately $4,949,500. This represents a 68.47% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold 36,413 shares of company stock valued at $18,251,464 in the last ninety days. Corporate insiders own 1.50% of the company’s stock.

Analyst Upgrades and Downgrades

HCA has been the topic of several research reports. KeyCorp raised their price target on HCA Healthcare from $435.00 to $490.00 and gave the company an “overweight” rating in a research note on Wednesday, October 28th. JPMorgan Chase & Co. lowered their price objective on shares of HCA Healthcare from $490.00 to $425.00 and set a “neutral” rating for the company in a research note on Thursday, August 20th. UBS Group dropped their target price on shares of HCA Healthcare from $635.00 to $579.00 and set a “buy” rating on the stock in a report on Monday, July 27th. Oppenheimer cut their target price on shares of HCA Healthcare from $520.00 to $485.00 and set an “outperform” rating on the stock in a research report on Monday, July 27th. Finally, Mizuho set a $495.00 price target on shares of HCA Healthcare in a report on Wednesday, October 28th. Sixteen analysts have rated the stock with a Buy rating, seven have assigned a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average target price of $480.13.

View Our Latest Stock Report on HCA Healthcare

Key Stories Impacting HCA Healthcare

These are some of the HCA stories that stood out recently:

  • Positive Sentiment: Value-focused articles describe HCA as a reasonably valued healthcare stock with long-term earnings-growth potential, supported by hospital demand and its scale. One analysis notes its valuation is below the sector median. Why HCA Healthcare is a Top Value Stock for the Long-Term
  • Neutral Sentiment: Zacks Research’s estimate changes were mixed: its FY2026 EPS forecast rose to $30.00, but it cut FY2027 to $30.87 and FY2028 to $33.98. The revisions offer a less uniformly strong forward earnings signal. HCA Healthcare analyst estimate updates
  • Negative Sentiment: Pomerantz LLP announced an investigation into claims on behalf of HCA investors. The announcement does not establish wrongdoing, but the added legal uncertainty could concern investors. Pomerantz investigation announcement

HCA Healthcare Company Profile

(Free Report)

HCA Healthcare is a healthcare services company that operates hospitals and other care facilities. Its services include inpatient and outpatient care, emergency treatment, surgery, diagnostic services and specialized care across areas such as cancer and cardiovascular medicine. The company serves patients in the United States and the United Kingdom through its network of hospitals and outpatient facilities, including surgery centers, urgent care clinics and physician practices. Founded in 1968, HCA Healthcare is headquartered in Nashville, Tennessee.

Read More

Want to see what other hedge funds are holding HCA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for HCA Healthcare, Inc. (NYSE:HCA – Free Report).

Institutional Ownership by Quarter for HCA Healthcare (NYSE:HCA)

Receive News & Ratings for HCA Healthcare Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for HCA Healthcare and related companies with MarketBeat.com's FREE daily email newsletter.